
Validea's Patient Investor model, based on Warren Buffett's strategy, rates semiconductor large-cap LAM RESEARCH CORP (LRCX) at 86%, signaling 'some interest' due to its alignment with criteria for predictable profitability, low debt, and reasonable valuations. The analysis highlights strong earnings predictability, debt management, and free cash flow, though it notably failed on return on total capital.
Lam Research Corp (LRCX) has been rated favorably at 86% by Validea's Patient Investor model, which emulates the investment criteria of Warren Buffett. This score indicates a significant alignment with the model's focus on long-term predictable profitability, low debt, and reasonable valuations for a large-cap growth stock in the semiconductor industry. The analysis identifies several core strengths, as LRCX passed key tests for earnings predictability, debt service capacity, return on equity, free cash flow generation, use of retained earnings, and share repurchases. These factors collectively point to a fundamentally sound business with disciplined capital management and a commitment to shareholder returns. However, the report flags a notable weakness, as the company failed the test for Return on Total Capital. This specific failure suggests a potential inefficiency in generating profits from its complete capital base, including both debt and equity, which contrasts with its otherwise strong performance metrics.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment